All In Biotech

Drug Trial Radar · NCT04774406

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Arterial Hypertension With PARP Inhibitors in Cancer Patients: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database (ArteRIB)

Last checked: Nov 19, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,336

Actual

Start

Feb 24, 2021

Primary completion

May 9, 2021

Study completion Sep 1, 2022

Sponsor

Lead sponsor
University Hospital, CaenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes

Summary

As written by the sponsor on the registry.

Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce. The objective was to investigate reports of hypertension related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.

Conditions

  • Cancer

Interventions

  • olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparibDrug

    All patients treated at least with 1 PARPi (alone or in combination)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. hypertension reports related to PARPi.Time frame: From inception to 16 Feb, 2023

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alexandre Joachim

    Caen, Basse Normandie, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.